<ѻýҕl>Medicaid Expansion Tied to Better Outcomes in Black Patients With GI Cancersѻýҕl> Two-year mortality decreased for three types of GI cancer in expansion vs non-expansion states May 25, 2023
<ѻýҕl>P53 Antagonist Shows Early Activity in Advanced Liposarcomaѻýҕl> ASCO roundup: ADC targeting CD46 slows mCRPC, molecule stabilizes effects of "hot spot" mutation Jun 08, 2022
<ѻýҕl>Intensified Regimen for Metastatic CRC Fails to Improve Outcomesѻýҕl> Combination of modified FOLFOXIRI/panitumumab also caused greater toxicity, study showed Jun 08, 2022
<ѻýҕl>A Better Way to Irradiate Lethal CNS Metastases?ѻýҕl> Randomized trial makes case for proton craniospinal irradiation for leptomeningeal spread Jun 08, 2022
<ѻýҕl>First-Line Anti-EGFR Extends OS in Left-Sided Colorectal Cancerѻýҕl> "A win for a highly selected group of patients," says ASCO expert Jun 07, 2022
<ѻýҕl>PARP Inhibitor Picks Up a Win in Frontline Maintenance for Ovarian Cancerѻýҕl> Median PFS more than doubled with rucaparib after response to platinum-based chemotherapy Jun 07, 2022
<ѻýҕl>Forego Radiotherapy for Women With Low-Risk Luminal A Breast Cancer?ѻýҕl> Study shows 5-year local recurrence rate of 2.3% with lumpectomy and endocrine therapy alone Jun 07, 2022
<ѻýҕl>Targeted Combo Topples Chemo in Pediatric Glioma With BRAF Mutationsѻýҕl> ORR quadrupled, median PFS nearly tripled with dabrafenib plus trametinib in low-grade disease Jun 06, 2022
<ѻýҕl>Radiation Alone May Suffice for Some Nasopharyngeal Cancerѻýҕl> Chemotherapy adds little benefit in intermediate grade lesions Jun 06, 2022
<ѻýҕl>Novel Agent Lessens Mucositis in Head and Neck Cancersѻýҕl> IV infusion could allow more patients to complete treatment regimen Jun 06, 2022
<ѻýҕl>Tiragolumab Fails in Extensive-Stage Small Cell Lung Cancerѻýҕl> No change in survival when combined with atezolizumab and chemotherapy Jun 06, 2022
<ѻýҕl>Liquid Biopsy May Save Colon Cancer Patients From Chemoѻýҕl> Circulating tumor DNA could determine who needs more therapy Jun 06, 2022
<ѻýҕl>Endocrine Switch Plus Ribociclib Active in Post-CDK4/6 Inhibitor Progressionѻýҕl> First randomized support for strategy in progressive metastatic HR+/HER2- breast cancer Jun 06, 2022
<ѻýҕl>Myeloma Trial Supports 'Personalized Approach' to Upfront Transplantѻýҕl> DETERMINATION confirms benefit in triple-therapy setting, but suggests timing can be tailored Jun 06, 2022
<ѻýҕl>Complete Responses in 100% of dMMR Rectal Cancer With Neoadjuvant PD-1 Inhibitionѻýҕl> Chemo, RT, surgery avoided in short-term follow-up but study population was small Jun 05, 2022
<ѻýҕl>Trastuzumab Deruxtecan Ushers in New Treatment Era for HER2-Low Breast Cancerѻýҕl> DESTINY-Breast04 extends agent's benefits to historically tough-to-treat disease Jun 05, 2022
<ѻýҕl>Will High-Dose Ifosfamide Become the Go-To Therapy in Recurrent Ewing Sarcoma?ѻýҕl> Data from European rEECur trial "are potentially practice changing," expert says Jun 05, 2022
<ѻýҕl>Third-Line BTK Inhibitor Combo Doubles PFS in Follicular Lymphomaѻýҕl> Significantly more responses, CRs with zanubrutinib-obinutuzumab versus anti-CD20 drug alone Jun 05, 2022
<ѻýҕl>Capivasertib-Fulvestrant Combo Ups Survival in ER+/HER2- Metastatic Breast Cancerѻýҕl> But benefit seems to be predominantly in patients with PI3K/AKT/PTEN pathway alterations Jun 05, 2022
<ѻýҕl>Sacituzumab Govitecan Boosts PFS in Late-Line HR+/HER2- Metastatic Breast Cancerѻýҕl> "This may be something that really changes the lives of these women for the better," expert says Jun 05, 2022
<ѻýҕl>Immunotherapy Rechallenge in NSCLC Yields Overall Survival Boostѻýҕl> Phase II trial sees "synergistic benefit" with checkpoint blockade and anti-angiogenesis Jun 04, 2022
<ѻýҕl>IL-15 Agonist Impresses in Non-Muscle Invasive Bladder Cancerѻýҕl> High response rate, 99%-100% cancer-specific survival at 2 years Jun 04, 2022
<ѻýҕl>Brentuximab Vedotin-Chemo Boosts EFS in High-Risk Pediatric Hodgkin Lymphomaѻýҕl> Combo regimen offers "a new standard for front-line therapy," researcher says Jun 04, 2022
<ѻýҕl>KRAS Inhibitor Shrinks Tumors in Over 40% of NSCLC Patientsѻýҕl> Median survival surpasses 1 year in heavily pretreated population Jun 03, 2022
<ѻýҕl>Add-On Ibrutinib Boosts PFS in Untreated, Older Mantle-Cell Lymphoma Patientsѻýҕl> BTK inhibitor plus chemoimmunotherapy increased progression-free survival by over 2 years Jun 03, 2022
<ѻýҕl>Survival Bump With EGFR Inhibitor for KRAS Wild-Type Pancreatic Cancerѻýҕl> But generalizability of "notable" Chinese study questioned Jun 03, 2022
<ѻýҕl>Increased Public Assistance Tied to Better Cancer Survival in Black Patientsѻýҕl> Disparity in 5-year OS declined by more than 40% with each 10% boost in public welfare spending May 31, 2022
<ѻýҕl>Cancer Outcome Disparities Not Fully Explained by Race, Socioeconomic Factorsѻýҕl> Worse 5-year OS in Hispanic children with high-risk neuroblastoma in adjusted analysis May 27, 2022
<ѻýҕl>COVID Increased Use of Telemedicine for Cancer Care, Though Not Equitablyѻýҕl> Black, uninsured, non-urban patients less likely to use these services May 26, 2022
<ѻýҕl>Black Patients Often Never Given a Chance to Join Breast Cancer Trialsѻýҕl> But survey finds several actionable findings that could boost enrollment May 26, 2022
<ѻýҕl>Tweaking Maintenance Options in Metastatic CRCѻýҕl> Two studies move the needle, but no major breakthroughs Jun 11, 2021
<ѻýҕl>Bispecific Antibody Active in NRG1-Positive Pancreatic Cancerѻýҕl> Zenocutuzumab turns in promising results in early-phase trial involving multiple solid tumors Jun 10, 2021
<ѻýҕl>Promising Early Data for Bladder-Sparing Cancer Treatmentѻýҕl> Bladder-intact DFS at 1 year nears 90% for muscle-invasive bladder cancer Jun 09, 2021
<ѻýҕl>TRK Inhibitor Proves Beneficial in Primary CNS Tumorsѻýҕl> One-year OS rate with larotrectinib was 85% Jun 09, 2021
<ѻýҕl>New Standard for Metastatic Castration-Sensitive Prostate Cancer?ѻýҕl> Triplet regimen reduced the risk for radiographic progression or death, but OS data await Jun 09, 2021
<ѻýҕl>'Important' Advance in Tough-to-Treat Thyroid Cancerѻýҕl> Targeted therapy cabozantinib may represent a new standard in heavily pretreated patients Jun 09, 2021
<ѻýҕl>More Support for Gene Assay to Guide Breast Cancer Treatmentѻýҕl> More nuanced data on treatment de-escalation, extended endocrine therapy Jun 09, 2021
<ѻýҕl>Another CAR-T Impresses in Follicular Lymphomaѻýҕl> Complete responses in 66% of patients with relapsed or refractory disease Jun 08, 2021
<ѻýҕl>BPAs Cut Fracture Risk in Metastatic Prostate Cancerѻýҕl> Those receiving enzalutamide with and without radium-223 saw benefits in updated safety analysis Jun 08, 2021
<ѻýҕl>Acalabrutinib Offers Less Wear and Tear on the Heart in CLL Patientsѻýҕl> BTK inhibitor had less cardiotoxicity than ibrutinib, but similar efficacy Jun 07, 2021